Blue Faery: The Adrienne Wilson Liver Cancer Association

09/17/2026

Sometimes support means talking with someone who understands the experience in a deeply personal way.

Through Blue Faery's partnership with CanCare, patients and caregivers can access free one-on-one peer support that offers encouragement and connection throughout the cancer journey.

Explore one-on-one support and see whether it's right for you.
https://vist.ly/5iuk5

09/16/2026

FDA Accepts NDA for Rivoceranib and Camrelizumab in 1L Unresectable HCC

The FDA has accepted a new drug application (NDA) resubmission for the combination of rivoceranib and camrelizumab as a first-line systemic treatment for patients with unresectable hepatocellular carcinoma (HCC), according to a press release from the developer, Elevar Therapeutics. The agency has assigned a Prescription Drug User Fee Act target action date of July 23, 2026.

Previously, the NDA for this combination in the aforementioned patient population has received 2 complete response letters (CRLs) from the FDA, with the first coming in May 2024 and the second in March 2025.2,3 The CRL issued by the FDA in May 2024 cited deficiencies related to the FDA’s inspection of the camrelizumab manufacturing facility, and in March 2025, the FDA requested more information on the treatment. The developer noted that the CRL did not identify any concerns regarding the clinical efficacy or safety of the combination therapy or the manufacturing process for rivoceranib.

“We will continue to work closely with Hengrui to ensure full readiness throughout the FDA review process, including the inspection of relevant manufacturing facilities,” stated Dong-Gun Kim, CEO of Elevar Therapeutics, in the press release. “We will also maintain proactive communication with the FDA and remain focused on achieving a successful outcome.” U.S. Food and Drug Administration https://vist.ly/5ipx7

Rivoceranib plus camrelizumab achieved a median OS of 23.8 months vs 15.2 months with sorafenib alone in patients with unresectable hepatocellular carcinoma.

09/15/2026

𝗛𝗶𝘀𝗽𝗮𝗻𝗶𝗰 𝗛𝗲𝗿𝗶𝘁𝗮𝗴𝗲 𝗠𝗼𝗻𝘁𝗵 is an opportunity to celebrate community, culture, and access to health information.

Blue Faery offers Spanish-language liver cancer education to help patients, caregivers, and families find trusted information they can watch and share at any time.

Explore our 𝗟𝗼𝘃𝗲 𝗬𝗼𝘂𝗿 𝗟𝗶𝘃𝗲𝗿 𝗛𝗶𝘀𝗽𝗮𝗻𝗶𝗰 𝗛𝗲𝗿𝗶𝘁𝗮𝗴𝗲 𝗠𝗼𝗻𝘁𝗵 𝗬𝗼𝘂𝗧𝘂𝗯𝗲 𝗽𝗹𝗮𝘆𝗹𝗶𝘀𝘁 and help us continue the conversation about liver health in our communities.

En español. Para nuestra comunidad.
https://vist.ly/5ijcr

09/14/2026

How a Simple Dietary Change May Slow Liver Cancer in At-Risk Patients

People with compromised liver function may be able to reduce their risk of liver cancer or slow its progression with a simple dietary change: eating less protein.

A Rutgers-led study in Science Advances found low-protein diets slowed liver tumor growth and cancer death in mice, uncovering a mechanism by which a liver's impaired waste-handling machinery can inadvertently fuel cancer.

Liver cancer remains one of the deadliest primary cancers in the United States, with a five-year survival rate of about 22%. The American Cancer Society estimates there were 42,240 new cases in 2025 and 30,090 deaths.

The number of U.S. residents with compromised liver function who face elevated cancer risk is far larger. About 1 in 4 U.S. adults has fatty liver disease, a condition that, along with viral hepatitis and heavy alcohol use, can raise the risk of cirrhosis as well as cancer.

"If you have liver disease or damage that prevents your liver from functioning correctly, you should seriously consider reducing your protein intake to lower the risk of developing liver cancer," said the study’s senior author, Wei-Xing Zong, a distinguished professor at the Rutgers Ernest Mario School of Pharmacy and a member of the Cancer Metabolism and Immunology Program at Rutgers Cancer Institute, the state’s only NCI-designated Comprehensive Cancer Center. Rutgers Cancer Institute American Cancer Society https://vist.ly/5ieqx

Rutgers researchers trace how excess protein fuels tumor growth when the liver's detox system is impaired.

09/11/2026

Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC

A new drug application (NDA) seeking the approval of rivoceranib plus camrelizumab as a potential first-line treatment for patients with unresectable hepatocellular carcinoma (HCC) has been resubmitted to the FDA, restarting the agency’s formal review of this regimen for a third time.

The resubmission follows the receipt of 2 complete response letters (CRLs) previously issued by the FDA. The initial CRL, issued on May 16, 2024, cited good manufacturing practice deficiencies at the Hengrui Pharma manufacturing facility responsible for producing camrelizumab, as well as incomplete bioresearch monitoring clinical inspections that were constrained by FDA travel restrictions. Importantly, the FDA did not identify deficiencies related to the clinical efficacy or safety data supporting the combination, nor were concerns raised regarding the manufacturing site for rivoceranib. Despite a subsequent resubmission, the agency issued a second CRL for the combination in the frontline unresectable HCC setting for reasons that were not publicly disclosed. U.S. Food and Drug Administration OncLive https://vist.ly/5i5kp

An NDA for rivoceranib plus camrelizumab in frontline HCC has been resubmitted to the FDA, following the company's receipt of 2 CRLs for this indication.

09/09/2026

New Research Shows Blood Test May Offer Early Warning of Liver Cancer Recurrence After Liver Transplant

A personalized blood test known as a circulating tumor DNA (ctDNA) test—which detects tiny fragments of cancer DNA circulating in the bloodstream—may help identify liver cancer recurrence earlier in transplant recipients and reduce the need for invasive procedures, according to a new study from Houston Methodist.

Published in the Journal of Gastrointestinal (GI) Oncology, the study was led by Dr. Maen Abdelrahim, director of the Cockrell Center for Advanced Therapeutics – Phase I program at the Houston Methodist Research Institute. Thirty-eight liver transplant recipients underwent ctDNA testing alongside standard cancer testing methods, including imaging and conventional tumor markers. Houston Methodist https://vist.ly/5hukj

09/08/2026

"Success isn't about winning awards. It's about seeing my patients live whole lives." Dr. Anjana Pillai, Medical Director at the University of Chicago, shares how her childhood in India shaped her approach to transplant oncology and treating the "intimidating" complexity of the liver.

Read her story: https://vist.ly/5hq3j

09/07/2026

Scientists Discover Potential New Cancer Treatment

By blocking this protein, the research team found that it may be possible to develop new treatments for specific cancers which hijack the body's growth system through this genetic error.

Bowel cancer remains the second most common cause of cancer death across the country, claiming around 1,700 lives annually.

While around 670 people die from liver cancer each year in Scotland so finding more effective ways to tackle the disease is vital.

Lead researcher on the project Prof Owen Sansom said: "Because NPM1 isn't essential for normal adult tissue health, blocking it could be a safe way to treat certain cancers, like some hard-to-treat bowel and liver cancers. https://vist.ly/5hk9v

The research focused on the genetic faults that allow the disease to hijack a signalling system in the body.

09/04/2026

HCC: LLM Advice and Treatment Concordance

Commonly used large language models (LLMs) were able to provide appropriate, guideline-aligned treatment recommendations for patients with straightforward cases of early-stage hepatocellular carcinoma; however, greater disagreement with physician recommendations was seen in cases of late-stage disease, according to findings from a Korean retrospective registry study published in PLOS Medicine.

“Our study shows that [LLMs] can help support treatment decisions for early-stage liver cancer, but their performance is more limited in advanced disease. This highlights the importance of using LLMs as a complement to, rather than a replacement for, clinical expertise,” the study authors, including corresponding author Ji Won Han, MD, PhD, Division of Gastroenterology and Hepatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, wrote. 가톨릭대학교 The Catholic University of Korea https://vist.ly/5hbsr

Commonly used large language models (LLMs) were able to provide appropriate, guideline-aligned treatment recommendations for patients with straightforward cases of early-stage hepatocellular carcinoma...

09/02/2026

Non-invasive Ultrasound Treatment for Liver Tumors Comes to Hackensack Meridian Jersey Shore University Medical Center

Patients with liver cancer or cancers that have spread to the liver will soon have an emerging, non-invasive option to consider at Hackensack Meridian Jersey Shore University Medical Center (JSUMC). The hospital is among only three in the state — and the only one in Monmouth and Ocean counties — that will offer the approach known as histotripsy, beginning in February. This innovative technology uses focused ultrasound waves to mechanically destroy tumors and cancerous tissue, turning them into liquid which the body naturally reabsorbs.

“This is one of the most fascinating technologies I’ve seen in my career,” said Gregory Tiesi, MD, FACS, FSSO, chief of surgical oncology at JSUMC. “Histotripsy uses a specialized device to focus ultrasound waves precisely on the targeted tumor, liquefying the tissue without damaging surrounding healthy structures. This precision allows us to preserve vital structures, without the risk of spreading cancer cells, and can be used in patients who might not otherwise have options like surgery.” Hackensack Meridian Health https://vist.ly/5g2nh

Available for cancerous and benign tumors; women who take oral contraceptives long term are at a 30% to 40% increase risk in developing benign liver tumors (ie. HCAs), which impact liver health